Page 9 - 24 May 2024 Current affairs

May 2024 Ki z
Ki z d
d
Cultivating Love for Learning

SCOPE Current Affairs

Nearly 100 Delhi-NCR schools receive bomb threats

possibly through Russian domain

Panic gripped Delhi-NCR region after nearly 100 schools
received bomb threats on Wednesday morning, reported PTI.
As per initial reports, Mother Mary School at Mayur Vihar, Delhi
Public School at Dwarka, Sanskriti School in Chanakyapuri,
Delhi Public School at Vasant Kunj and Amity School in Saket
are some of the schools which received bomb threats via email.
The Union Home Ministry on Wednesday termed the bomb
threat to schools in the city and adjoining areas as a "hoax", and
asked people not to panic. Police and security agencies are
taking necessary steps as per protocol, the ministry said.
"There is no need to panic. Mails appears to be hoax. Delhi Police and security agencies are taking
necessary steps as per protocol," a home ministry official said.
AstraZeneca Admits Covishield Jab Has Rare Side-

Effect.

Thrombosis Thrombocytopenia Syndrome (TTS) - a blood clot
disorder - is a rare side effect of AstraZeneca's Covid vaccine,
and the risks far outweigh the benefits of the jab, doctors said.
This comes after reports said that AstraZeneca has for the first
time accepted in court documents that its vaccine, developed in
partnership with Oxford University, can raise the risk of a rare
and serious blood clot.
The Oxford-AstraZeneca Covid vaccine, sold as Covishield in
India and Vaxzevria in Europe is a viral vector vaccine
developed using the modified chimpanzee adenovirus ChAdOx1.
Covishield manufactured and marketed in India in partnership with Serum Institute of India (SII), was widely
administered in the country - to almost 90 per cent of the Indian population.
"Thrombotic Thrombocytopenic Syndrome (TTS) is one of the rare but very serious adverse effects that has
happened as part of Vaccine-induced Immune Thrombotic Thrombocytopenic Purpura (VITTP). The
incidence has been as low as one in 50,000 (0.002 per cent), but in a huge population, the number becomes
sizeable," infectious disease expert Dr. Ishwar Gilada, told IANS.